VBCN - May 2015 Volume 2, No 1

Patients receiving treatment of relapse-remitting multiple sclerosis (RRMS) progressed significantly slower than predicted, leading investigators to suggest that RRMS treatment is both clinically and cost-effective.

The results from 3 studies demonstrate the efficacy of teriflunomide on reducing relapses across a range of patients, including those with early and relapsing multiple sclerosis

As one center showed, streamlined coordination among emergency department physicians, pharmacists, and neurologists can improve outcomes of patients diagnosed with stroke.

Patients with primary and secondary progressive multiple sclerosis (MS) showed improvements in standard measures of physical and neurologic disability after taking high doses of biotin (300 mg daily) for 1 year, according to results of a phase 3 clinical trial presented at the 2015 annual meeting of the American Academy of Neurology.

An in-depth analysis from the randomized, controlled Netherlands Subthalamic and Pallidal Stimulation (NSTAPS) clinical trial found no substantial differences in neuropsychological outcomes in patients with Parkinson disease who received globus pallidus internus (GPi) deep brain stimulation (DBS) or subthalamic nucleus (STN) DBS.

In the largest study of its kind, a team of neuroscientists concluded that socioeconomic adversity affects brain development in children.

The treatment of headache for more than 12 million Americans costs more than $31 billion yearly.

A new study unveils a strong association between Epstein-Barr virus (EBV) genomic variants and multiple sclerosis, reinforcing the idea that EBV contributes to the development of multiple sclerosis.

Lightning bolt images in the dendrites of brain cells may reveal how the brain sorts, stores, and interprets information during learning, according to researchers at New York University (NYU) Langone Medical Center.